Resolian Bioanalytics has acquired China-based bioanalytical CRO Denali Medpharma to add reach and oligo capabilities to its offering.
In addition to the technical capabilities, the deal – financial terms of which were not disclosed – is designed to boost Resolian’s geographic reach according to Resolian CEO, Patrick Bennett.
“The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market.”
Chongqing-based Denali provides bioanalysis services for oligonucleotide drugs, mRNA vaccines, liposome encapsulated medicines. It also provides assay development services for inhaled therapeutics.
The firm’s customer base includes Shijiazhuang, China headquartered drug maker CSPC Ouyi Pharmaceutical, whose generic version of the cancer therapy irinotecan hydrochloride liposome for injection was approved by Chinese authorities in September.
Denali has a 70-stong team, all of whom will be joining Resolian according to Bennett.
“Denali’s founders and core scientists are internationally recognized across pharmaceutical research and development analysis and we are particularly excited to add Denali’s oligo, mRNA, and liposomal expertise to Resolian’s portfolio of services.
“We look forward to leveraging our growing company’s strengths to continue driving innovation and creating lasting value for our clients and stakeholders.”
Denali CEO, Min Meng, agreed, added that the team’s experience providing services for drug firms working in China and overseas would be of benefit.
“Denali was founded by a group of US-trained bioanalytical experts in a state-of-the-art lab facility in China to provide exceptional service for domestic and international clients.
“We look forward to continuing this track record and offering even greater capabilities and trial flexibility as part of Resolian.”
Resolian was formed in 2022 when Malvern Pennsylvania, US-headquartered Alliance Pharma acquired UK-based counterpart Drug Development Solutions.